Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)

被引：0

作者：

Cavo, Michele ^{[1
]}

Corradini, Paolo ^{[2
]}

Di Raimondo, Francesco ^{[3
]}

Petrini, Mario ^{[4
]}

Cafro, Anna Maria ^{[5
]}

di Toritto, Tommaso Caravita ^{[6
]}

Offidani, Massimo ^{[7
]}

Semenzato, Gianpietro ^{[8
]}

Zambello, Renato ^{[9
]}

Lazzaro, Antonio ^{[10
,11
]}

Petrucci, Maria Teresa ^{[12
]}

Rodeghiero, Francesco ^{[13
]}

Simcock, Mathew ^{[14
]}

Slaughter, Ana ^{[14
]}

Herring, Jennifer ^{[15
]}

Peluso, Teresa ^{[14
]}

Palumbo, Antonio ^{[16
]}

机构：

[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[3] Univ Catania, Dept Clin & Mol Biomed, Catania, Italy

[4] Univ Pisa, Hematol, Pisa, Italy

[5] Osped Niguarda Ca Granda, Milan, Italy

[6] S Eugenio Hosp, Div Hematol, Rome, Italy

[7] Osped Riuniti Ancona, Haematol Clin, Ancona, Italy

[8] Venetian Inst Mol Med, Padua, Italy

[9] Univ Padua, Sch Med, Hematol & Clin Immunol Sect, Dept Med, Padua, Italy

[10] Hosp Piacenza, Hematol Unit, Piacenza, Italy

[11] Hosp Piacenza, Bone Marrow Transplant Ctr, Piacenza, Italy

[12] Univ Roma La Sapienza, Dept Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy

[13] S Bortolo Hosp, Dept Cell Therapy & Hematol, Vicenza, Italy

[14] Celgene Int Sarl, Boudry, Switzerland

[15] Celgene Corp, Summit, NJ USA

[16] Univ Turin, Turin, Italy

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
San-Miguel, Jesus F.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David Samuel DiCapua
Palumbo, Antonio
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin W.
Sternas, Lars Axel
Peluso, Teresa
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed H.
Miguel, Jesus San
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[43] MANAGEMENT OF ADVERSE EVENTS IN THE STRATUS TRIAL, A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Cavo, M.
Dimopoulos, M. A.
Moreau, P.
Palumbo, A.
Corradini, P.
Weisel, K.
Ocio, E.
Doyen, C.
Anttila, P.
Raymakers, R.
San Miguel, J.
Yu, X.
Milller, N.
Herring, J.
Slaughter, A.
Peluso, T.
Sternas, L.
Zaki, M.
Delforge, M.
HAEMATOLOGICA, 2015, 100 : 253 - 254
[44] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
San Miguel, Jesus F.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine I.
Renner, Christoph
Bahlis, Nizar J.
Yu, Xin
Teasdale, Terri
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
BLOOD, 2013, 122 (21)
[45] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
De Miguel, D.
Gil, A.
Golbano, N.
Diaz, M.
Guillen, H.
Vazquez, A.
Pinedo, B.
HAEMATOLOGICA, 2017, 102 : 790 - 791
[46] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Mikhael, J.
Richardson, P.
Usmani, S.
Raje, N.
Bensinger, W.
Kanagavel, D.
Gao, L.
Ziti-ljajic, S.
Anderson, K.
HAEMATOLOGICA, 2017, 102 : 168 - 168
[47] MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT
Matous, J.
Siegel, D.
Duong, H.
Kasserra, C.
Sternas, L.
Jacques, C.
Klesczewski, K.
Zaki, M.
Shah, J.
HAEMATOLOGICA, 2013, 98 : 323 - 323
[48] A STATISTICAL COMPARISON OF THE EFFICACY AND SAFETY OF LOW-DOSE LENALIDOMIDE plus LOW- DOSE DEXAMETHASONE WITH FULL-DOSE LENALIDOMIDE plus DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Quach, H.
Fernyhough, L.
Henderson, R.
Corbett, G.
Honemann, D.
Blacklock, H.
Browett, P.
Link, E.
Cowan, L.
Li, J.
Swern, A.
Hussein, M.
Lynch, K.
Dimopoulos, M.
Prince, M.
HAEMATOLOGICA, 2012, 97 : 350 - 351
[49] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Spencer, Andrew
Knop, Stefan
Renner, Christoph
Bahlis, Nizar J.
Amatya, Ramesh
Yu, Xin
Monzini, Mara Silvia
Sternas, Lars
Zaki, Mohamed H.
Jacques, Christian J.
San Miguel, Jesus F.
BLOOD, 2013, 122 (21)
[50] Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study
Lonial, Sagar
Baz, Rachid
Bahlis, Nizar J.
Chen, Christine I.
Anderson, Kenneth C.
Chen, Min
Zaki, Mohamed
Richardson, Paul G.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →